IGC Pharma (IGC) Cash & Current Investments (2010 - 2026)
IGC Pharma (IGC) posted quarterly Cash & Current Investments of $263000.0 for Q1 2026, down 35.06% year-over-year from $405000.0 in Q1 2025, and down 73.05% quarter-over-quarter from $976000.0 in Q4 2025.
IGC Pharma (IGC) Cash & Current Investments (2010 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Cash & Current Investments for 17 consecutive years, with $263000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash & Current Investments fell 35.06% year-over-year to $263000.0; the TTM figure through Mar 2026 stood at $263000.0 (down 35.06% YoY), while the FY2026 annual figure was $263000.0, down 35.06% from the prior year.
- Cash & Current Investments eased to $263000.0 in Q1 2026 per IGC's latest filing, from $976000.0 in the prior quarter.
- Across five years, Cash & Current Investments topped out at $10.5 million in Q1 2022 and bottomed at $263000.0 in Q1 2026.
- Historically, Cash & Current Investments has averaged $2.9 million across 5 years, with a median of $1.5 million in 2024.
- Annual changes were most pronounced in 2023 — Cash & Current Investments plunged 75.79% — and 2025, when it jumped 107.66%.
- IGC Pharma's Cash & Current Investments stood at $5.0 million in 2022, then tumbled by 72.62% to $1.4 million in 2023, then plunged by 65.89% to $470000.0 in 2024, then soared by 107.66% to $976000.0 in 2025, then tumbled by 73.05% to $263000.0 in 2026.
- Business Quant data shows IGC's Cash & Current Investments at $263000.0 in Q1 2026, $976000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | IGC Pharma | 30.17 Mn | 29.90 Mn | - | 263,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 263,000.00 |
| Dec 31, 2025 | 976,000.00 |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 454,000.00 |
| Mar 31, 2025 | 405,000.00 |
| Dec 31, 2024 | 470,000.00 |
| Sep 30, 2024 | 1.55 Mn |
| Jun 30, 2024 | 1.82 Mn |
| Mar 31, 2024 | 1.20 Mn |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.95 Mn |
| Mar 31, 2023 | 3.50 Mn |
| Dec 31, 2022 | 5.03 Mn |
| Sep 30, 2022 | 6.82 Mn |
| Jun 30, 2022 | 8.05 Mn |
| Mar 31, 2022 | 10.46 Mn |
| Dec 31, 2021 | 11.94 Mn |
| Sep 30, 2021 | 14.40 Mn |
| Jun 30, 2021 | 13.32 Mn |